| # | Title | Journal | Year | Citations |
|---|
| 1 | Pancreatic cancer | Lancet, The | 2020 | 1,376 |
| 2 | Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) | Lancet, The | 2017 | 1,032 |
| 3 | Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Annals of Oncology | 2016 | 523 |
| 4 | Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor | Cancer Research | 2010 | 468 |
| 5 | Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial | Lancet Oncology, The | 2021 | 396 |
| 6 | Significance of CD44 and CD24 as Cancer Stem Cell Markers: An Enduring Ambiguity | Clinical and Developmental Immunology | 2012 | 385 |
| 7 | Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma | Cancer Discovery | 2013 | 300 |
| 8 | Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging | Clinical Cancer Research | 2007 | 293 |
| 9 | Heparan sulfate: growth control with a restricted sequence menu | Journal of Clinical Investigation | 2001 | 281 |
| 10 | The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors | Journal of Immunotherapy | 2005 | 258 |
| 11 | Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer | Annals of Oncology | 2008 | 247 |
| 12 | The Interaction of the Transforming Growth Factor-βs with Heparin/Heparan Sulfate Is Isoform-specific | Journal of Biological Chemistry | 1997 | 236 |
| 13 | Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma | Clinical Cancer Research | 2010 | 236 |
| 14 | Neuropilin-1 Binds Vascular Endothelial Growth Factor 165, Placenta Growth Factor-2, and Heparin via Its b1b2 Domain | Journal of Biological Chemistry | 2002 | 227 |
| 15 | Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer | Breast Cancer Research and Treatment | 2006 | 218 |
| 16 | Biomarkers of angiogenesis and their role in the development of VEGF inhibitors | British Journal of Cancer | 2010 | 217 |
| 17 | Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study | Bone Marrow Transplantation | 2016 | 216 |
| 18 | Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production | Cell Cycle | 2012 | 209 |
| 19 | Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study | Annals of Oncology | 2017 | 201 |
| 20 | Isolation of germ cells from human testicular tissue for low temperature storage and autotransplantation | Fertility and Sterility | 2001 | 194 |
| 21 | Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation | JAMA Oncology | 2021 | 194 |
| 22 | HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparin-bound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1 | BMC Biochemistry | 2006 | 192 |
| 23 | Fibroblast growth factors and their receptors: An information network controlling tissue growth, morphogenesis and repair | Progress in Growth Factor Research | 1994 | 173 |
| 24 | ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy. | Journal of Clinical Oncology | 2019 | 166 |
| 25 | VEGF165-binding Sites within Heparan Sulfate Encompass Two Highly Sulfated Domains and Can Be Liberated by K5 Lyase | Journal of Biological Chemistry | 2006 | 145 |
| 26 | Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial | Lancet, The | 2019 | 142 |
| 27 | Lomeguatrib, a Potent Inhibitor of O6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors | Clinical Cancer Research | 2006 | 136 |
| 28 | Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer | Clinical Cancer Research | 2004 | 135 |
| 29 | Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial | Lancet Oncology, The | 2019 | 131 |
| 30 | Differential Effects of Heparin Saccharides on the Formation of Specific Fibroblast Growth Factor (FGF) and FGF Receptor Complexes | Journal of Biological Chemistry | 2002 | 130 |
| 31 | Essential Alterations of Heparan Sulfate During the Differentiation of Embryonic Stem Cells to Sox1-Enhanced Green Fluorescent Protein-Expressing Neural Progenitor Cells | Stem Cells | 2007 | 126 |
| 32 | Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours | British Journal of Cancer | 2012 | 122 |
| 33 | Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry | Journal of Hepatology | 2022 | 119 |
| 34 | A New Model for the Domain Structure of Heparan Sulfate Based on the Novel Specificity of K5 Lyase | Journal of Biological Chemistry | 2004 | 117 |
| 35 | Highly Sensitive Sequencing of the Sulfated Domains of Heparan Sulfate | Journal of Biological Chemistry | 1999 | 116 |
| 36 | Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2 | Glycobiology | 2000 | 105 |
| 37 | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial | Annals of Oncology | 2020 | 105 |
| 38 | Epidermal growth factor receptor tyrosine kinase inhibitors | British Journal of Cancer | 2004 | 103 |
| 39 | A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer | BMC Cancer | 2006 | 103 |
| 40 | Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial | Journal of Clinical Endocrinology and Metabolism | 2015 | 99 |
| 41 | Oligosaccharide mapping of heparan sulphate by polyacrylamide-gradient-gel electrophoresis and electrotransfer to nylon membrane | Biochemical Journal | 1988 | 97 |
| 42 | CAR T cells: driving the road from the laboratory to the clinic | Immunological Reviews | 2014 | 96 |
| 43 | Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma | Journal of Clinical Oncology | 2007 | 95 |
| 44 | T regulatory cells in cancer: recent advances and therapeutic potential | Expert Opinion on Biological Therapy | 2010 | 94 |
| 45 | Fibrillin-1 Interactions with Heparin | Journal of Biological Chemistry | 2005 | 88 |
| 46 | Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study | Blood | 2020 | 86 |
| 47 | Antiangiogenic drugs in ovarian cancer | British Journal of Cancer | 2009 | 84 |
| 48 | Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling | Breast Cancer Research | 2013 | 82 |
| 49 | A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial | Annals of Oncology | 2017 | 82 |
| 50 | MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum | Journal of Clinical Oncology | 2020 | 82 |
